Telix Pharmaceuticals Ltd: Becoming a substantial holder
Telix Pharmaceuticals Ltd: Telix Submits NDA for TLX101-CDx Brain Cancer Imaging Agent
Telix Pharmaceuticals Ltd: Telix Reorganisation to Deliver on Strategic Priorities
Telix Pharmaceuticals Ltd: Ceasing to be a substantial holder
Telix Pharmaceuticals Ltd: Securities Dealing Policy - Updated
Telix Pharmaceuticals Ltd: Telix 1H 2024 Results Presentation
Telix Pharmaceuticals Ltd: Telix 1H 2024 Results Release
Telix Pharmaceuticals Ltd: Telix 1H 2024 Appendix 4D and Interim Report
Telix Pharmaceuticals Ltd: Becoming a substantial holder
Telix Pharmaceuticals Ltd: Ceasing to be a substantial holder
Telix Pharmaceuticals Ltd: Telix 2024 Half-Year Results Investor Webcast Notification
Telix Pharmaceuticals Ltd: Becoming a substantial holder
Telix Pharmaceuticals Ltd: Ceasing to be a substantial holder
Telix Pharmaceuticals Ltd: Ceasing to be a substantial holder
Telix Pharmaceuticals Ltd: Investor Conference Call - TLX250-CDx BLA Filing Update
Telix Pharmaceuticals Ltd: BLA Filing Update for Renal Cancer Imaging Agent TLX250-CDx
Telix Pharmaceuticals Ltd: Appendix 3G
Telix Pharmaceuticals Ltd: Telix Completes A$650 Million of Convertible Bonds
Telix Pharmaceuticals Ltd: Convertible Bond Cleansing Notice
Telix Pharmaceuticals Ltd: Becoming a substantial holder
No Data